Skip to main content
. 2022 Nov 30;10(11):e005619. doi: 10.1136/jitc-2022-005619

Figure 6.

Figure 6

The percentages of different immune cells subtypes in tumor tissues among eight treatment groups. (A) Representative dot plots of the morphological characteristics (SSC vs FSC) exhibited by triple combination treated tumors (RFH+LTX-315 (L-315)+DOX). Schematic illustration of gating: Tumor-infiltrating lymphocytes determined by forward and side scatter properties, stained with relevant antibodies for flow cytometric analysis, to identify NK (CD3–/NKR-P1A+) cell and T (CD3+/NKR-P1A–) cell populations (including CD4+ and CD8+ T-cell subsets). The percentage of Tregs is derived from the percentage of Foxp3+ cells within the total CD4+ T-cell population. The percentage of CD8+/IFN-γ+ T cells or CD8+/TNF-α+ T cells is derived from the percentage of IFN-γ+ or TNF-α+ cells within the total CD8+ T-cell population. Quantitative analysis further displays a significantly higher percentage of CD8+ T cells, CD8+/IFN-γ+ T cells, CD8+/TNF-α+ T cells (B–D), and NK cells (E), a significantly lower percentage of Tregs (F), and a significantly higher ratio of pro-immune (CD8+/IFN-γ+ T cells+CD8+/TNF-α+ T cells) to Tregs (G) in the triple combination treatment group, compared with other seven treatment groups (**p<0.01, ***p<0.001). n=6 in each group. Error bars represent SD. FSC-A, forward scatter area; IFN, interferon; NK, natural killer; RFH, radiofrequency hyperthermia; SSC-A, side scatter area; TNF, tumor necrosis factor; Treg, regulatory T cells.